U.S. flag An official website of the United States government.
Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Advisory Committee on Immunization Practices (ACIP)

CDC Stacks Public Health Publications

The ACIP is a group of medical and public health experts that develops recommendations on the use of vaccines in the civilian population of the United States. The ACIP holds three meetings each year at the Centers for Disease Control and Prevention (CDC), in Atlanta, Georgia to make vaccine recommendations. Meetings are open to the public and available online via webcast. More information on ACIP is available at: https://www.cdc.gov/vaccines/acip/index.html.

(93)
(134)
(235)
(276)
(178)
(127)
(140)
(113)
(96)
(84)
(115)
(117)
(125)
(16)
(24)
(16)
(19)
(13)
(17)
(9)
(8)
(15)
(11)
(6)
(10)
(10)
(5)
(10)
(11)
(5)
(8)
(9)
(6)
(9)
(8)
(7)
(6)
(10)
(5)
(6)
(5)
(6)
(6)
(5)
(5)
(6)
(9)
(3)
(8)
(4)
(3)
(2)
(5)
(3)
(2)
(4)
(3)
(3)
(2)
(2)
(1)
0 of 61
(12)
(32)
(108)
(40)
(11)
(1)
(1)
(49)
(1)
(51)
(49)
(17)
(11)
(1293)
(499)
(7)
0 of 16
(1)
(1)
(1)
(4)
(2)
(1)
(1)
(2)
(5)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(5)
(1)
(1)
(5)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(451)
(1)
(1)
(1)
(1)
(1)
(1)
0 of 46
(1)
(1)
(1)
0 of 3
(10)
(5)
(1)
(4)
(2)
(1)
(1)
(4)
(1)
(5)
(1)
(1)
(2)
(1)
(2)
(2)
(1)
(1)
(1)
(1)
(138)
(1)
(158)
(1)
(33)
(66)
(1)
(1)
(73)
(19)
(2)
(12)
(19)
(1)
(4)
(1)
(1)
(1)
(1)
(2)
(1)
(31)
(2)
(3)
(1)
(2)
(2)
(3)
(6)
(1)
(1)
(10)
(1)
(3)
(2)
(2)
(14)
(2)
(2)
(3)
(5)
(2)
(1)
(9)
(3)
(1)
(2)
(2)
(4)
(1)
(1)
(1)
(1)
(5)
(3)
(1)
(7)
(1)
(10)
(1)
(1)
(10)
(1)
(2)
(2)
(1)
(1)
(2)
(1)
(1)
(7)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(3)
(1)
(12)
(2)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(12)
(2)
(2)
(1)
(3)
(9)
(1)
(6)
(1)
(1)
(6)
(2)
(2)
(10)
(1)
(1)
(2)
(1)
(1)
(1)
(2)
(3)
(3)
(1)
(11)
(2)
(2)
(4)
(1)
(3)
(13)
(8)
(158)
(111)
(1)
(2)
(2)
(1)
(1)
(11)
(1)
(1)
(10)
(2)
(7)
(2)
(1)
(1)
(1)
(7)
(15)
(4)
(2)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(20)
(5)
(200)
(45)
(4)
(2)
(19)
(2)
(3)
(2)
(82)
(257)
(6)
(23)
(1)
(3)
(1)
(1)
(8)
(1)
(4)
(2)
(1)
(1)
(119)
(7)
(5)
(3)
(1)
(1)
(1)
(3)
(1)
(1)
(4)
(35)
(2)
(1)
(16)
(2)
(12)
(1)
(32)
(2)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(3)
(22)
(1)
(2)
(2)
(10)
(2)
(2)
(2)
(3)
(1)
(1)
(2)
(23)
(9)
(4)
(1)
(5)
(1)
(1)
(1)
(15)
(1)
(3)
(1)
(9)
(1)
(2)
(4)
(1)
(2)
(2)
(1)
(1)
(1)
(2)
(2)
(1)
(4)
(1)
(1)
(1)
(17)
(1)
(1)
(2)
(2)
(1)
(1)
(2)
(3)
(1)
(1)
(3)
(2)
(1)
(2)
(1)
(5)
(1)
(1)
(1)
(1)
(1)
(2)
(2)
(1)
(4)
(3)
(9)
(2)
(5)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(3)
(54)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(2)
(1)
(21)
(3)
(1)
(5)
(1)
(1)
(15)
(1)
(56)
(1)
(2)
(5)
(1)
(2)
(2)
(1)
(1)
(3)
(5)
(2)
(1)
(15)
(1)
(1)
(2)
(2)
(1)
(3)
(1)
(33)
(2)
(1)
(3)
(2)
(3)
(1)
(19)
(2)
(2)
(4)
(4)
(2)
(1)
(2)
(1)
(2)
(5)
(7)
(1)
(1)
(1)
(7)
(9)
(9)
(1)
(1)
(3)
(1)
(26)
(3)
(1)
(2)
(1)
(1)
(10)
(1)
(2)
(1)
(1)
(39)
(2)
(1)
(1)
(1)
(3)
(4)
(1)
(2)
(3)
(1)
(35)
(1)
(1)
(1)
(7)
(1)
(9)
(1)
(2)
(10)
(11)
(1)
(1)
(1)
(1)
(6)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(167)
(1)
(1)
(5)
(1)
(1)
(4)
(345)
(6)
(3)
(76)
(2)
(2)
(1)
(1)
(1)
(2)
(50)
(7)
(4)
(321)
(1)
(1)
(1)
(192)
(1)
(2)
(17)
(3)
(2)
(3)
(3)
(1)
(1)
(1)
(1)
(6)
(1)
(6)
(110)
(2)
(72)
(1)
(6)
(2)
(3)
(1)
(1)
(1)
(1)
(39)
(1)
(10)
(1)
(11)
(4)
(26)
(15)
(2)
(1)
(2)
(1)
(3)
(10)
(4)
(15)
(2)
(13)
(2)
(18)
(6)
(2)
(1)
(1)
(2)
(2)
(4)
(173)
(18)
(2)
(1)
(11)
(5)
(2)
(2)
(2)
(1)
(1)
(1)
(2)
(2)
(2)
(2)
(2)
(2)
(2)
(3)
(1)
(1)
(1)
(1)
(12)
(3)
(2)
(4)
(1)
(1)
(1)
(1)
(1)
(3)
(1)
(1)
(10)
(1)
(4)
(1)
(1)
(31)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(5)
(3)
(2)
(6)
(1)
(13)
(4)
(2)
(2)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(42)
(1)
(2)
(8)
(1)
(1)
(11)
(1)
(1)
(6)
(28)
(1)
(1)
(1)
(2)
(1)
(7)
(1)
(9)
(1)
(2)
(1)
(2)
(1)
(2)
(3)
(4)
(1)
(1)
(3)
(14)
(3)
(1)
(10)
(2)
(1)
(104)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(71)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(15)
(1)
(3)
(2)
(3)
(3)
(4)
(15)
(12)
(3)
(2)
(4)
(3)
(1)
(6)
(1)
(7)
(1)
(1)
(5)
(1)
(13)
(2)
(2)
(1)
(1)
(2)
(1)
(5)
(2)
(1)
(1)
(1)
(1)
(1)
(3)
(4)
(1)
(1)
(1)
(4)
(1)
(7)
(1)
(3)
(6)
(2)
(1)
(2)
(1)
(2)
(1)
(7)
(1)
(1)
(1)
(2)
(1)
(1)
(29)
(1)
(152)
(1)
(5)
(1)
(1)
(1)
(3)
(2)
(56)
(1)
(1)
(34)
(1)
(8)
(1)
(1)
(1)
(1)
(1)
(56)
(1)
(2)
(1)
(6)
(1)
(1)
(1)
(35)
(2)
(1)
(2)
(1)
(1)
(6)
(1)
(1)
(1)
(1)
(1)
(17)
(1)
(1)
(8)
(1)
(91)
(3)
(1)
(2)
(4)
(1)
(1)
(11)
(2)
(3)
(1)
(3)
(1)
(1)
(4)
(2)
(6)
(2)
(2)
(1)
(8)
(2)
(1)
(5)
(1)
(10)
(13)
(1)
(6)
(1)
(2)
(1)
(6)
(1)
(35)
(1)
(9)
(1)
(65)
(1)
(6)
(3)
(2)
(1)
(2)
(1)
(2)
(2)
(28)
(2)
(1)
(3)
(1)
(1)
(4)
(1)
(1)
(3)
(3)
(1)
(16)
(1)
(1)
(1)
(4)
(2)
(14)
(1)
(1)
(4)
(3)
(2)
(11)
(1)
(1)
(1)
(4)
(5)
(2)
(5)
(11)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(2)
(1)
(1)
(1)
(10)
(5)
(2)
(1)
(56)
(14)
(48)
(10)
(13)
(1)
(1)
(1)
(2)
(1)
(4)
(18)
(12)
(1)
(1)
(3)
(9)
(1)
(2)
(1)
(3)
(1)
(1)
(1)
(1)
(1)
(1)
(5)
(2)
(32)
(5)
(2)
(13)
(5)
(1)
(1)
(2)
(19)
(1)
(6)
(2)
(1)
(2)
(1)
(2)
(2)
(1)
(1)
(11)
(2)
(1)
(4)
(2)
(1)
(1)
(2)
(1)
(1)
(26)
(2)
(2)
(1)
(2)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(3)
(11)
(1)
(1)
(1)
(2)
(1)
(2)
(1)
(1)
(2)
(3)
(2)
(8)
(1)
(5)
(4)
(8)
(5)
(1)
(1)
(1)
(1)
(1)
(21)
(1)
(1)
(2)
(1)
(7)
(3)
(2)
(4)
(2)
(1)
(2)
(2)
(1)
(1)
(629)
(17)
(2)
(1)
(1)
(5)
(1)
(1)
(23)
(22)
(5)
(4)
(1)
(1)
(13)
(379)
(1)
(28)
(23)
(23)
(1)
(1)
(1)
(21)
(1)
(1)
(1)
(9)
(3)
(51)
(2)
(1)
(11)
(18)
(2)
(2)
(5)
(3)
(12)
(2)
(170)
(2)
(23)
(2)
(10)
(4)
(2)
(2)
(2)
(11)
(2)
(2)
(2)
(2)
(43)
(2)
(4)
0 of 1000
(1)
(1)
(3)
(2)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(3)
(1)
(2)
(1)
(2)
(1)
(1)
(3)
(2)
(1)
(1)
(1)
(7)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(7)
(1)
(9)
(1)
(1)
(1)
(1)
(1)
(3)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(39)
(2)
(1)
(8)
(16)
(1)
(4)
(4)
(2)
(3)
(1)
(1)
(1)
(1)
(1)
(2)
(2)
(4)
(2)
(1)
(1)
(3)
(23)
(1)
(1)
(8)
(2)
(1)
(11)
(1)
(1)
(1)
(15)
(1)
(1)
(14)
(1)
(1)
(5)
(1)
(2)
(1)
(1)
(3)
(8)
(21)
(1)
(1)
(9)
(1)
(3)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(16)
(2)
(1)
(1)
(1)
(1)
(4)
(1)
(1)
(1)
(9)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(10)
(1)
(1)
(2)
(7)
(1)
(1)
(5)
(1)
(8)
(2)
(5)
(10)
(2)
(1)
(1)
(2)
(2)
(2)
(22)
(3)
(4)
(4)
(4)
(3)
(1)
(22)
(1)
(7)
(1)
(4)
(2)
(2)
(1)
(4)
(4)
(2)
(32)
(2)
(1)
(1)
(1)
(6)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(3)
(1)
(31)
(3)
(1)
(5)
(1)
(1)
(2)
(1)
(1)
(3)
(1)
(2)
(1)
(7)
(1)
(4)
(1)
(1)
(4)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(2)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(4)
(2)
(2)
(3)
(1)
(7)
(2)
(1)
(1)
(10)
(10)
(1)
(11)
(2)
(6)
(1)
(1)
(2)
(2)
(1)
(1)
(2)
(1)
(1)
(9)
(4)
(2)
(1)
(1)
(1)
(5)
(8)
(1)
(1)
(5)
(7)
(1)
(1)
(1)
(1)
(3)
(2)
(2)
(1)
(12)
(1)
(2)
(5)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(5)
(1)
(1)
(2)
(1)
(51)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(3)
(1)
(2)
(1)
(1)
(4)
(2)
(1)
(15)
(1)
(4)
(8)
(2)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(4)
(7)
(1)
(3)
(3)
(1)
(4)
(4)
(1)
(1)
(3)
(5)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(14)
(20)
(2)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(2)
(2)
(12)
(1)
(1)
(1)
(1)
(9)
(1)
(8)
(1)
(1)
(1)
(1)
(1)
(2)
(8)
(1)
(1)
(1)
(2)
(3)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(3)
(1)
(1)
(7)
(1)
(11)
(1)
(2)
(2)
(1)
(1)
(1)
(13)
(1)
(1)
(1)
(1)
(6)
(1)
(1)
(7)
(2)
(1)
(1)
(1)
(4)
(3)
(1)
(1)
(1)
(1)
(11)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(7)
(21)
(2)
(1)
(3)
(7)
(3)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(15)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(3)
(34)
(2)
(1)
(2)
(8)
(3)
(1)
(1)
(1)
(1)
(2)
(1)
(15)
(1)
(1)
(1)
(5)
(1)
(13)
(1)
(1)
(1)
(1)
(1)
(2)
(2)
(7)
(1)
(9)
(1)
(1)
(1)
(1)
(1)
(1)
(7)
(1)
(14)
(9)
(1)
(1)
(1)
(1)
(2)
(1)
(4)
(1)
(1)
(1)
(1)
(1)
(3)
(11)
(1)
(37)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(8)
(1)
(1)
(1)
(4)
(2)
(10)
(1)
(8)
(1)
(1)
(1)
(1)
(1)
(5)
(1)
(5)
(3)
(2)
(2)
(1)
(1)
(4)
(6)
(8)
(1)
(6)
(1)
(2)
(1)
(3)
(5)
(2)
(4)
(2)
(5)
(1)
(2)
(1)
(1)
(2)
(1)
(5)
(1)
(11)
(2)
(1)
(3)
(1)
(4)
(2)
(1)
(12)
(2)
(2)
(6)
(1)
(9)
(2)
(1)
(2)
(1)
(7)
(7)
(1)
(1)
(2)
(1)
(11)
(8)
(1)
(2)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(3)
(54)
(2)
(4)
(4)
(1)
(1)
(2)
(1)
(3)
(1)
(1)
(6)
(9)
(3)
(1)
(1)
(1)
(1)
(2)
(2)
(3)
(1)
(1)
(4)
(1)
(3)
(1)
(1)
(6)
(3)
(2)
(2)
(1)
(1)
(1)
(4)
(7)
(2)
(4)
(1)
(8)
(1)
(1)
(25)
(1)
(1)
(10)
(17)
(1)
(2)
(1)
(1)
(2)
(1)
(1)
(6)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(14)
(4)
(3)
(2)
(1)
(2)
(1)
(2)
(1)
(1)
(1)
(18)
(1)
(2)
(1)
(1)
(7)
(1)
(2)
(10)
(1)
(1)
(1)
(1)
(30)
(2)
(2)
(2)
(1)
(1)
(1)
(1)
(2)
(3)
(2)
(1)
(3)
(1)
(2)
(1)
(19)
(1)
(2)
(2)
(1)
(1)
(1)
(1)
(1)
(8)
(1)
(1)
(30)
(5)
(1)
(11)
(3)
(1)
(1)
(2)
(1)
(2)
(2)
(8)
(1)
(1)
(1)
(1)
(1)
(7)
(4)
(2)
(1)
(4)
(2)
(1)
(2)
(1)
(4)
(1)
(1)
(1)
(1)
(2)
(1)
(8)
(2)
(1)
(1)
(2)
(45)
(1)
(1)
(7)
(1)
(3)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(5)
(10)
(1)
(1)
(1)
(10)
(1)
(1)
(13)
(1)
(8)
(7)
(2)
(2)
(1)
(8)
(8)
(2)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(7)
(8)
(2)
(1)
(32)
(2)
(1)
(1)
(1)
(2)
(1)
(1)
(10)
(1)
(1)
(2)
(1)
(2)
(1)
(3)
(5)
(4)
(1)
(2)
(2)
(1)
(1)
(9)
(1)
(2)
(2)
(10)
(1)
(1)
(1)
(2)
(1)
(5)
(1)
(1)
(4)
(2)
(2)
(26)
(1)
(1)
(24)
(1)
(1)
(1)
(3)
(1)
(1)
(2)
(4)
(5)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(5)
(4)
(2)
(2)
(1)
(1)
(11)
(3)
(1)
(4)
(1)
(1)
(5)
(1)
(2)
(9)
(1)
(1)
(6)
(2)
(1)
(3)
(1)
(1)
(1)
(1)
(3)
(1)
(1)
(1)
(2)
(2)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
0 of 893
(2)
(1)
(1)
(3)
(1)
(1)
(2)
(2)
(5)
(24)
(3)
(4)
(6)
(1)
(16)
(21)
(9)
(1)
(1)
(1)
(1)
(6)
(3)
(1)
(4)
(2)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(3)
(1)
(8)
(1)
(3)
(6)
(1)
(1)
(2)
(14)
(1)
(1)
(1)
(1)
(2)
(1)
(2)
(29)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(3)
(1)
(2)
(50)
(113)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(9)
(1)
(1)
(1)
(5)
(1)
(1)
(1)
(1)
(1)
(6)
(1)
(1)
(2)
(2)
(9)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(2)
(1)
(1)
(2)
(4)
(1)
(1)
(1)
(5)
(1)
(11)
(1)
(2)
(1)
(1)
(4)
(2)
(1)
(1)
(1)
(1)
(4)
(2)
(1)
(1)
(1)
(6)
(1)
(1)
(8)
(1)
(2)
(7)
(5)
(1)
(1)
(5)
(2)
(6)
(1)
(1)
(1)
(12)
(1)
(9)
(2)
(1)
(5)
(3)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(5)
(4)
(3)
(4)
(1)
(16)
(11)
(1)
(8)
(6)
(1)
(3)
(1)
(5)
(1)
(3)
(25)
(3)
(8)
(1)
(1)
(1)
(30)
(4)
(6)
(1)
(44)
(30)
(1)
(1)
(1)
(4)
(1)
(1)
(1)
(9)
(1)
(10)
(14)
(2)
(10)
(1)
(90)
(1)
(1)
(1)
(1)
(1)
(1)
(7)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(46)
(4)
(3)
(2)
(66)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(83)
(1)
(1)
(1)
(2)
(53)
(1)
(1)
(1)
(4)
(1)
(1)
(1)
(3)
(2)
(6)
(9)
(1)
(10)
(1)
(1)
(2)
(3)
(6)
(2)
(1)
(5)
(4)
(1)
(3)
(2)
(1)
(1)
(13)
(4)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(10)
(1)
(22)
(3)
(7)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(2)
(4)
(1)
(1)
(1)
(4)
(9)
(1)
(2)
(1)
(1)
(1)
(3)
(1)
(2)
(3)
(3)
(1)
(2)
(10)
(1)
(6)
(1)
(1)
(11)
(1)
(1)
(1)
(1)
(3)
(1)
(7)
(1)
(1)
(1)
(1)
(1)
(13)
(1)
(14)
(547)
(1)
(1)
(1)
(6)
(1)
(3)
(1)
(4)
(10)
(1)
(15)
(11)
(14)
(1)
(4)
(4)
(1)
(2)
(2)
(5)
(1)
(4)
(1)
(162)
(1)
(5)
(1)
(3)
(7)
(3)
(1)
(33)
(2)
(14)
(3)
(3)
(9)
(2)
(1)
(10)
(1)
(2)
(30)
(6)
(1)
(4)
(4)
(5)
(2)
(7)
(1)
(6)
(2)
(1)
(19)
(15)
(1)
(1)
(9)
(5)
(1)
(2)
(2)
(18)
(3)
(5)
(46)
(2)
(1)
(2)
(3)
(2)
(1)
(3)
(4)
(1)
(5)
(1)
(1)
(4)
(3)
(1)
(1)
(7)
(2)
(2)
(3)
(1)
(1)
(1)
(2)
(1)
(1)
(2)
(3)
(7)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(10)
(3)
(2)
(3)
(1)
(1)
(1)
(5)
(1)
(1)
(1)
(1)
(1)
(11)
(1)
(1)
(1)
(3)
(1)
(2)
(1)
0 of 463
(1)
(74)
(1)
(1)
(1)
(1624)
(32)
(7)
(10)
(1)
(13)
(99)
(200)
(10)
(12)
(34)
(1292)
(1)
(38)
(1)
(2)
(2)
(62)
(1)
(1)
(1)
0 of 26
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(2)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
(1)
0 of 18
(1)
0 of 1
Showing 1861 - 1880 of 2199 results
  • FDA licensure of bivalent human papillomavirus vaccine HPV2 Cervarix for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices ACIP
    FDA licensure of bivalent human papillomavirus vaccine (HPV2, Cervarix) for use in females and updated HPV vaccination recommendations from the Advisory Committee on Immunization Practices (ACIP)
    United States. Advisory Committee on Immunization Practices.  ...
    May 28, 2010 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
    On October 16, 2009, the Food and Drug Administration (FDA) licensed bivalent human papillomavirus vaccine (HPV2; Cervarix, GlaxoSmithKline) for use in females aged 10 through 25 years. Cervarix is the second human papillomavirus (HPV) vaccine licensed for use in females in the United States. Quadrivalent HPV vaccine (HPV4; Gardasil, Merck & Co, In ...
    Current Public Domain
  • FDA licensure of quadrivalent human papillomavirus vaccine HPV4 Gardasil for use in males and guidance from the Advisory Committee on Immunization Practices ACIP
    FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP)
    United States. Advisory Committee on Immunization Practices.  ...
    May 28, 2010 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
    To develop the 1993 Sexually Transmitted Diseases Treatment Guidelines, experts from the Centers for Disease Control and Prevention reviewed the literature on sexually transmitted disease treatment, assembled tables of evidence, and listed key questions on therapeutic outcome: microbiologic cure, alleviation of symptoms, and prevention of sequelae ...
    Superseded Public Domain
  • Morbidity and Mortality Weekly Report Recommendations and Reports May 7 2010 Vol 59 No RR3
    Morbidity and Mortality Weekly Report: Recommendations and Reports, May 7, 2010 / Vol. 59 / No. RR-3
    Marin, Mona ;
    Broder, Karen R.
    May 7, 2010 | Recommendations and Reports: Morbidity and Mortality Weekly Report (MMWR)
    This report presents new recommendations adopted in June 2009 by CDC's Advisory Committee on Immunization Practices (ACIP) regarding use of the combination measles, mumps, rubella, and varicella vaccine (MMRV, ProQuad, Merck & Co., Inc.). MMRV vaccine was licensed in the United States in September 2005 and may be used instead of measles, mumps, rub ...
    Current Public Domain
  • Morbidity and Mortality Weekly Report Recommendations and Reports March 19 2010 Vol 59 No RR2
    Morbidity and Mortality Weekly Report: Recommendations and Reports, March 19, 2010 / Vol. 59 / No. RR-2
    Briggs, Deborah ;
    Brown, Catherine M.
    March 19, 2010 | Recommendations and Reports: Morbidity and Mortality Weekly Report (MMWR)
    "These recommendations of the Advisory Committee on Immunization Practices (ACIP) update the previous recommendations on human rabies prevention (CDC. Human rabies prevention---United States, 1999: recommendations of the Advisory Committee on Immunization Practices. MMWR 1999;48 [No. RR-1]) and reflect the status of rabies and antirabies biologics ...
    Public Domain
  • Licensure of a 13valent pneumococcal conjugate vaccine PCV13 and recommendations for use among children Advisory Committee on Immunization Practices ACIP 2010
    Licensure of a 13-valent pneumococcal conjugate vaccine (PCV13) and recommendations for use among children - Advisory Committee on Immunization Practices (ACIP), 2010.
    United States. Advisory Committee on Immunization Practices.
    March 12, 2010 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
    On February 24, 2010, a 13-valent pneumococcal conjugate vaccine (PCV13 [Prevnar 13, Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc.]) was licensed by the Food and Drug Administration (FDA) for prevention of invasive pneumococcal disease (IPD) caused by the 13 pneumococcal serotypes covered by the vaccine and for prevention of otitis media ...
    Superseded Public Domain
  • Licensure of a meningococcal conjugate vaccine Menveo and guidance for use Advisory Committee on Immunization Practices ACIP 2010
    Licensure of a meningococcal conjugate vaccine (Menveo) and guidance for use - Advisory Committee on Immunization Practices (ACIP), 2010.
    United States. Advisory Committee on Immunization Practices.
    March 12, 2010 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
    On February 19, 2010, the Food and Drug Administration (FDA) licensed a quadrivalent meningococcal conjugate vaccine, MenACWY-CRM (Menveo, Novartis Vaccines and Diagnostics). MenACWY-CRM is licensed as a single dose for use among persons aged 11-55 years. The Advisory Committee on Immunization Practices (ACIP) reviewed data from prelicensure clinic ...
    Superseded Public Domain
  • Morbidity and Mortality Weekly Report Recommendations and Reports March 12 2010 Vol 59 No RR1
    Morbidity and Mortality Weekly Report: Recommendations and Reports, March 12, 2010 / Vol. 59 / No. RR-1
    Fischer, Marc ;
    Hills, Susan
    March 12, 2010 | Recommendations and Reports: Morbidity and Mortality Weekly Report (MMWR)
    "This report updates the 1993 recommendations by CDC's Advisory Committee on Immunization Practices (ACIP) regarding the prevention of Japanese encephalitis (JE) among travelers (CDC. Inactivated Japanese encephalitis virus vaccine: recommendations of the Advisory Committee on Immunization Practices [ACIP]. MMWR 1993;42[No. RR-1]). This report summ ...
    Current Public Domain
  • Agenda Meeting of the Advisory Committee on Immunization Practices ACIP February 2425 2010 Atlanta Georgia
    [Agenda] : Meeting of the Advisory Committee on Immunization Practices (ACIP) : February 24-25, 2010, Atlanta, Georgia
    United States. Advisory Committee on Immunization Practices.
    01/28/2010 | ACIP Meetings Agenda
    ACIP Meeting agenda, February 24-25, 2010
    Public Domain
  • Recommended adult immunization schedule United States 2010
    Recommended adult immunization schedule -- United States, 2010
    United States. Advisory Committee on Immunization Practices.  ...
    January 15, 2010 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
    The Advisory Committee on Immunization Practices (ACIP) annually reviews the recommended Adult Immunization schedule reflects current recommendations for the licensed vaccines. In October 2009, ACIP approved the Adult Immunization Schedule for 2010, which includes several changes. A bivalent human papillomavirus vaccine (HPV2) was licensed for use ...
    Superseded Public Domain
  • Recommended immunization schedules for persons aged 0 through 18 years United States 2010
    Recommended immunization schedules for persons aged 0 through 18 years -- United States, 2010
    United States. Advisory Committee on Immunization Practices.  ...
    January 8, 2010 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
    The Advisory Committee on Immunization Practices (ACIP) annually publishes an immunization schedule for persons aged 0 through 18 years that summarizes recommendations for currently licensed vaccines for children aged 18 years and younger and includes recommendations in effect as of December 15, 2009. Changes to the previous schedule (1) include th ...
    Superseded Public Domain
  • Advisory Committee on Immunization Practices ACIP summary report February 2627 2014 Atlanta Georgia
    Advisory Committee on Immunization Practices (ACIP) summary report : February 26-27, 2014, Atlanta, Georgia
    United States. Advisory Committee on Immunization Practices.
    2010 | ACIP: Meeting Agenda, Minutes, etc.
    No Description
    Public Domain
  • Advisory Committee on Immunization Practices ACIP summary report October 2728 2010 Atlanta Georgia
    Advisory Committee on Immunization Practices (ACIP) summary report : October 27-28, 2010, Atlanta, Georgia
    United States. Advisory Committee on Immunization Practices.
    2010 | ACIP: Meeting Agenda, Minutes, etc.
    min-oct10.pdf
    Public Domain
  • Advisory Committee on Immunization Practices ACIP summary report February 2425 2010 Atlanta Georgia
    Advisory Committee on Immunization Practices (ACIP) summary report : February 24-25, 2010, Atlanta, Georgia
    United States. Advisory Committee on Immunization Practices.
    2010 | ACIP: Meeting Agenda, Minutes, etc.
    min-feb10.pdf
    Public Domain
  • Updated Recommendation from the Advisory Committee on Immunization Practices ACIP for Revaccination of Persons at Prolonged Increased Risk for Meningococcal Disease
    Updated Recommendation from the Advisory Committee on Immunization Practices (ACIP) for Revaccination of Persons at Prolonged Increased Risk for Meningococcal Disease
    United States. Advisory Committee on Immunization Practices.
    September 25, 2009 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
    The Advisory Committee on Immunization Practices (ACIP) recommends quadrivalent meningococcal conjugate vaccine, (MCV4) (Menactra, Sanofi Pasteur, Swiftwater, Pennsylvania) for all persons aged 11-18 years and for persons aged 2-55 years at increased risk for meningococcal disease. MCV4 is licensed as a single dose. Because of the high risk for men ...
    Superseded Public Domain
  • Updated Recommendations from the Advisory Committee on Immunization Practices ACIP for Use of Hepatitis A Vaccine in Close Contacts of newly Arriving International Adoptees
    Updated Recommendations from the Advisory Committee on Immunization Practices (ACIP) for Use of Hepatitis A Vaccine in Close Contacts of newly Arriving International Adoptees
    National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention (U.S.). Division of Viral Hepatitis.  ...
    September 18, 2009 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
    On February 25, 2009, the Advisory Committee on Immunization Practices (ACIP) recommended routine hepatitis A vaccination for household members and other close personal contacts (e.g., regular babysitters) of adopted children newly arriving from countries with high or intermediate hepatitis A endemicity. This new recommendation complements previous ...
    Current Public Domain
  • Morbidity and Mortality Weekly Report Recommendations and Reports August 28 2009 Vol 58 No RR10
    Morbidity and Mortality Weekly Report: Recommendations and Reports, August 28, 2009 / Vol. 58 / No. RR-10
    United States. Advisory Committee on Immunization Practices.  ...
    August 28, 2009 | Recommendations and Reports: Morbidity and Mortality Weekly Report (MMWR)
    "This report provides recommendations by CDC's Advisory Committee on Immunization Practices (ACIP) regarding the use of vaccine against infection with novel influenza A (H1N1) virus. Information on vaccination for seasonal influenza has been published previously (CDC. Prevention and control of seasonal influenza with vaccines: recommendations of th ...
    Superseded Public Domain
  • Updated Recommendations of the Advisory Committee on Immunization Practices ACIP regarding routine poliovirus vaccination
    Updated Recommendations of the Advisory Committee on Immunization Practices (ACIP) regarding routine poliovirus vaccination
    United States. Advisory Committee on Immunization Practices.
    August 7, 2009 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
    This report updates Advisory Committee on Immunization Practices (ACIP) recommendations for routine poliovirus vaccination. These updates aim to 1) emphasize the importance of the booster dose at age >/=4 years, 2) extend the minimum interval from dose 3 to dose 4 from 4 weeks to 6 months, 3) add a precaution for the use of minimum intervals in the ...
    Current Public Domain
  • Morbidity and Mortality Weekly Report Recommendations and Reports July 31 2009 Vol 58 No RR8
    Morbidity and Mortality Weekly Report: Recommendations and Reports, July 31, 2009 / Vol. 58 / No. RR-8
    Bresee, Joseph S. ;
    Broder, Karen R.
    July 31, 2009 | Recommendations and Reports: Morbidity and Mortality Weekly Report (MMWR)
    This report updates the 2008 recommendations by CDC's Advisory Committee on Immunization Practices (ACIP) regarding the use of influenza vaccine for the prevention and control of seasonal influenza (CDC. Prevention and control of influenza: recommendations of the Advisory Committee on Immunization Practices [ACIP]. MMWR 2008;57[No. RR-7]). Informat ...
    Superseded Public Domain
  • Agenda Meeting of the Advisory Committee on Immunization Practices ACIP Wednesday July 29 2009 Atlanta Georgia
    [Agenda] : Meeting of the Advisory Committee on Immunization Practices (ACIP) : Wednesday July 29, 2009 , Atlanta, Georgia
    United States. Advisory Committee on Immunization Practices.
    07/21/2009 | ACIP Meetings Agenda
    ACIP Meeting agenda, Wednesday July 29, 2009
    Public Domain
  • Updated Recommendations for use of Haemophilus influenzae Type b Hib Vaccine Reinstatement of the Booster Dose at Ages 1215 Months
    Updated Recommendations for use of Haemophilus influenzae Type b (Hib) Vaccine: Reinstatement of the Booster Dose at Ages 12-15 Months
    United States. Advisory Committee on Immunization Practices.  ...
    June 26, 2009 | Weekly Report: Morbidity and Mortality Weekly Report (MMWR)
    On December 13, 2007, certain lots of Haemophilus influenzae type b (Hib) vaccine marketed as PedvaxHIB (monovalent Hib vaccine) and Comvax (Hib-HepB vaccine), and manufactured by Merck & Co., Inc., were recalled voluntarily, and the company temporarily suspended production of these vaccines. To conserve the limited supply of Hib-containing vaccine ...
    Retired Public Domain
1861 - 1880 / 2199